Fundraising FoxMVM Life Science Partners — 2016 Investments
2 investments dated 2016 · listed companies and verified rows first · show all
Tarsa Therapeutics developed TBRIA, an oral formulation of calcitonin for treating postmenopausal osteoporosis in women more than five years post menopause when other treatments are unsuitable.
BiotechPhiladelphia, US
David Brand(Executive Officer, Director)inGregory Lumpkin(Executive Officer)
BoardRichard Kollender(Director)Martin Edwards(Director)Derek Ferguson(Director)
Board seatEric Bednarski· per SEC Form D
Co-investorsForesite CapitalOxford Finance LLCQuaker BioVentures
Biotheranostics develops proprietary genomic assays used to support personalized disease management in oncology.
BiotechHealthtechMedical DevicesSan Diego, US
Nicholas Barthelemy(Executive Officer, Director, Promoter)
BoardDavid Kabakoff(Director)inEric Bednarski(Director)Alejandro Sanchez(Director)in
Co-investorsEvidity Health CapitalHealthQuest Capital
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.